Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exagen Inc. - Common Stock (NQ:XGN)

4.430 -0.060 (-1.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exagen Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
Exagen: Q2 Earnings Insights
Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results. Quarterly Results Earnings per share were down 40.74% over the past year to ($0.38), which beat the... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Exagen: Q1 Earnings Insights
Shares of Exagen (NASDAQ:XGN) were flat after the company reported Q1 results. Quarterly Results Earnings per share were down 9.09% year over year to ($0.48), which missed the... 
Via Benzinga
Exagen Stock Gains As Q2 Financials Surpass Street Expectations
Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
Exagen Inc. (XGN) Q2 2021 Earnings Call Transcript
XGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Return On Capital Employed Overview: Exagen
In Q1, Exagen (NASDAQ:XGN) posted sales of $10.59 million. Earnings were up 101.63%, but Exagen still reported an overall loss of $5.57 million. In Q4, Exagen brought in $12.67... 
Via Benzinga
Exagen: Return On Capital Employed Insights
During Q1, Exagen's (NASDAQ:XGN) reported sales totaled $10.59 million. Despite a 101.63% in earnings, the company posted a loss of $5.57 million. Exagen collected $12.67 million... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Curis, Inc. (NASDAQ: CRIS) shares surged 65.5% to settle at $16.27 on Wednesday in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA... 
Via Benzinga
Exagen Inc. (XGN) Q1 2021 Earnings Call Transcript
XGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021
Upgrades According to JP Morgan, the prior rating for Vipshop Holdings Ltd (NYSE:VIPS) was changed from Neutral to Overweight. In the fourth quarter, Vipshop Holdings... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.